Atomo Diagnostics (ASX:AT1) EBITDA Margin %: -100.38% (As of Dec. 2025)


What is Atomo Diagnostics EBITDA Margin %?

Atomo Diagnostics ASX:AT1 EBITDA Margin % is -100.38% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Atomo Diagnostics ranks worse than 83.82% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Atomo Diagnostics's EBITDA for the six months ended in Dec. 2025 was A$-2.14 Mil. Atomo Diagnostics's Revenue for the six months ended in Dec. 2025 was A$2.13 Mil. Therefore, Atomo Diagnostics's EBITDA margin for the quarter that ended in Dec. 2025 was -100.38%.

Atomo Diagnostics  (ASX:AT1) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Atomo Diagnostics EBITDA Margin % Related Terms

Atomo Diagnostics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Atomo Diagnostics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics EBITDA Margin % Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial -69.91 -29.94 -366.19 -134.60 -104.13

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -150.65 -120.43 -103.12 -105.53 -100.38

ASX:AT1 vs ABT, SYK, MDT: EBITDA Margin % Comparison

For the Medical Devices subindustry, Atomo Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atomo Diagnostics EBITDA Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Atomo Diagnostics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Atomo Diagnostics's EBITDA Margin % falls into.


Atomo Diagnostics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Atomo Diagnostics's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-3.382/3.248
=-104.13 %

Atomo Diagnostics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-2.137/2.129
=-100.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -100.38% mean?
Atomo Diagnostics (ASX:AT1) has a EBITDA Margin % of -100.38% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Atomo Diagnostics and its competitors. According to the industry distribution chart, Atomo Diagnostics ranks #684 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 83.8%.
Is Atomo Diagnostics' EBITDA Margin % too high?
Atomo Diagnostics' current EBITDA Margin % is -100.38%. Based on the distribution chart, Atomo Diagnostics ranks #684 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Atomo Diagnostics' EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Atomo Diagnostics ranks #684 out of 816 companies for EBITDA Margin %. This places Atomo Diagnostics in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Atomo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atomo Diagnostics's current EBITDA Margin % is -100.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current EBITDA Margin % is -100.38%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current EBITDA Margin % is -100.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atomo Diagnostics Business Description

Address 3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.